dexfenfluramine (Redux)
Jump to navigation
Jump to search
Introduction
Tradename: Redux. DEA-controlled substance: class 2. DEA-controlled substance: class 4[3].
FDA approved in 1996.
Withdrawn from US market is 1997[2].
Indications
Dosage
Tabs: 15 mg.
Pharmacokinetics
- eliminated by liver
- 1/2life: 11-30 hours
elimination via liver
1/2life = 11-30 hours
Adverse effects
pulmonary hypertension (23-46/100,000)
- drug adverse effects of analeptics
- drug adverse effects of psychotropic agents
- drug adverse effects of sympathomimetic(s)
More general terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Jump up to: 2.0 2.1 Fresno Bee, Dec. 2000
- ↑ Jump up to: 3.0 3.1 Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 461